LEXINGTON, Mass., June 2 /PRNewswire/ -- RainDance Technologies, Inc., a provider of innovative microdroplet-based solutions for human health and disease research, today announced the appointment of Roch W. Kelly as Chief Operating Officer, effective immediately.
"As RainDance solutions enter commercial development, Mr. Kelly is the ideal leader to establish our manufacturing and financial capabilities," said Chris McNary, President and Chief Executive Officer, RainDance Technologies. "With more than 20 years of experience in life sciences, he brings a proven record of successfully implementing the process and controls in these critical areas to meet the anticipated demand for our products."
Kelly joins RainDance from Synarc, Inc., where he was Vice President, Clinical Operations. Under his leadership, the operational team rapidly implemented new processes and systems that achieved a 25% improvement in efficiency. Previous positions included Chief Operating Officer and Chief Financial Officer at Protedyne, Inc., and Vice President, Clinical Operations and Worldwide Business, at PAREXEL International. He also served as Executive Director of Manufacturing Operations at Chiron Diagnostics. Kelly received a Bachelor of Science degree in finance from Miami (Ohio) University and a Master of Business Administration degree from Syracuse University.
About RainDance Technologies, Inc.
RainDance Technologies is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company's exciting new technology enable researchers to design experiments in ways that were previously unaffordable or unimaginable.
The company's technology produces picoliter-sized droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt highly referenced assays for high-speed workflows with minimized process-induced bias or error.
RainDance's initial application will focus on the targeted resequencing of the human genome -- one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.
RainDance was founded in 2004 by scientists from Harvard University; the Medical Research Centre in Cambridge, England; and the ESPCI in Paris. The promise of this technology has attracted an outstanding Scientific Advisory Board. RainDance advisers include three Nobel Prize winners: Jean-Marie Lehn (Chemistry, 1987), Aaron Klug (Chemistry, 2002), and Richard Roberts (Physiology or Medicine, 1993), as well as Sir Gregory Winter, joint head of the British Division of Protein and Nucleic Acids Chemistry at the Medical Research Council's Laboratory of Molecular Biology in Cambridge.
For more information, please visit http://www.raindancetechnologies.com.
CONTACT: Corporate: Steve Becker, beckers@raindancetechnologies.com, or
Technical: Jeremy Lambert, lambertj@raindancetechnologies.com, both of
RainDance Technologies, Inc., +1-781-861-6300
Web site: http://www.raindancetechnologies.com/